The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.
The Toronto-based partners aim to create a rapid, multiplex test and companion point-of-care device for identifying lung transplant candidates.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.
The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.
The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.
The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
In a recent study in Blood, the researchers showed that a higher allelic burden after transplantation was associated with higher risk of relapse and mortality.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.